Diagnos Inc.

Diagnos Inc.

October 26, 2011 15:59 ET

DIAGNOS Announces Correction to a News Release Dated September 6, 2011

BROSSARD, QUEBEC--(Marketwire - Oct. 26, 2011) - DIAGNOS inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in the use of artificial intelligence and advanced knowledge-extraction techniques, announces a correction to a news release dated September 6, 2011 with regards to the exercise price per share of the first tranche of stock options granted to Mr. Morin.

The exercise price for the first tranche is C$0.325 compared to C$0.29 as previously announced. Thus, the fourth paragraph of the news release should read: The service contract is for twelve (12) months for a monthly retainer of C$6,000. Furthermore, on August 30, 2011, the Board of Directors has approved a grant of 250,000 stock options, subject to regulatory approval, to Mr. Morin, under the terms of the share stock option plan of the Corporation approved by the Shareholders in September 2008. The exercise price has been established at C$0.325 per share for the first tranche of 33% options vested one year after the grant date, C$0.35 per share for second tranche of 33% options vested after two years of the grant date and C$0.40 per share for the last tranche vested three years after the grant date. The expiry date where these options can be exercised has been fixed to September 5, 2016.


Founded in 1998, DIAGNOS is a publicly traded Canadian corporation (TSX VENTURE:ADK), with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare, natural resources, and entertainment.

For further information, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information